Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.23 USD
Change Today -0.02 / -0.62%
Volume 7.4M
SNSS On Other Exchanges
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

sunesis pharmaceuticals inc (SNSS) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/27/14 - $8.46
52 Week Low
10/13/14 - $1.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

sunesis pharmaceuticals inc (SNSS) Related Businessweek News

No Related Businessweek News Found

sunesis pharmaceuticals inc (SNSS) Details

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. The company was founded in 1998 and is headquartered in South San Francisco, California.

39 Employees
Last Reported Date: 03/12/15
Founded in 1998

sunesis pharmaceuticals inc (SNSS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $488.1K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $390.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $420.9K
Compensation as of Fiscal Year 2014.

sunesis pharmaceuticals inc (SNSS) Key Developments

Sunesis Pharmaceuticals, Inc.(NasdaqCM:SNSS) dropped from Russell 2000 Index

Sunesis Pharmaceuticals, Inc. will be removed from Russell 2000 Index

Sunesis Pharmaceuticals, Inc.(NasdaqCM:SNSS) dropped from Russell 3000 Index

Sunesis Pharmaceuticals, Inc. will be removed from Russell 3000 Index.

Sunesis Pharmaceuticals Announces Presentations of VALOR Data at the 20th Congress of the European Hematology Association

Sunesis Pharmaceuticals, Inc. announced that two poster presentations describing results from the VALOR trial will be presented at the 20th Congress of the European Hematology Association (EHA) being held June 11 – 14, 2015, at the Reed Messe Wien Exhibition & Congress Center in Vienna, Austria. VALOR is a randomized, double-blind, placebo-controlled Phase 3 trial which enrolled 711 adult patients with first relapsed or refractory AML at 124 leading sites in 15 countries. Patients were stratified for age, geographic region and disease status and randomized one to one to receive either vosaroxin and cytarabine or placebo and cytarabine.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNSS:US $3.23 USD -0.02

SNSS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NeurogesX Inc $0.0065 USD -0.0025
POZEN Inc $10.70 USD -0.55
View Industry Companies

Industry Analysis


Industry Average

Valuation SNSS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 44.3x
Price/Book 13.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUNESIS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at